Business Wire Feed

QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast

January 19th, 2026|

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025. Press release date / time: Wednesday, February 4 shortly after 22:05 Frankfurt time more...

Naturmega® Announces Peer-Reviewed Clinical Results for Ruby-O® Balance, Demonstrating Stronger Triglyceride Responder Outcomes with a Lower Omega-3 Dose

January 19th, 2026|

Published in BMC Complementary Medicine and Therapies, the study validates Ruby-O®’s bonded phospholipid omega-3 platform as a more efficient, cell-oriented approach to omega-3 delivery.BARRANQUILLA, Colombia--(BUSINESS WIRE)--#CardiometabolicHealth--Naturmega, a pioneer in advanced lipid science, announced the results more...

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

January 19th, 2026|

Multi-year global collaboration will utilize Guardant liquid biopsy portfolio for the development of companion diagnostics for drug approvalsPALO ALTO, Calif.--(BUSINESS WIRE)--$GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration more...

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

January 16th, 2026|

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued more...

Spark® Green Apple Candy Makes Its New Year Debut

January 16th, 2026|

This Limited‑Time Flavor Brings Sweet Candy Energy to the New YearRICHARDSON, Texas--(BUSINESS WIRE)--#AdvoCareRehydrate--Ring in the new year with Spark® Green Apple Candy, available for a limited time and bringing crave‑worthy sweet candy flavor to fuel more...

OrsoBio Announces Nature Medicine Publication Establishing Clinical and Mechanistic Validation of First-in-Class LXR Inverse Agonist TLC-2716 for the Treatment of Serious Metabolic Diseases

January 16th, 2026|

Findings confirm translation from human genetics, organoid systems, and preclinical models to Phase 1 clinical findingsMENLO PARK, Calif.--(BUSINESS WIRE)--#NatureMedicine--OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.